Published May 25, 2004
by Humana Press .
Written in English
|The Physical Object|
|Number of Pages||328|
The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment Brand: Humana Press. Clinical molecular diagnostics for proteasome inhibitors in cancer therapy / Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds and James Stec Phase II trials of bortezomib for the treatment of multiple myeloma / Kenneth C. Anderson. The proteasome inhibitor bortezomib (VELCADE®, formerly known as PS), has recently been approved in the United States for treatment of patients with multiple myeloma who have received at least two prior therapies, and have demonstrated disease progression on their last by: Proteasome Inhibitors in Cancer Therapy Author: Julian Adams PhD Published by Humana Press ISBN: DOI: /
following proteasome inhibition. 5. Detail the status of various proteasome inhibitors in pre-clinical and clinical trials. chemotherapy is an established means for cancer. ABSTRACT: The cellular proteasome is an important molecular target in cancer therapy and drug resistance research. Proteasome inhibitors are effective agents. The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed by: Use of proteasome inhibitors in anticancer therapy S. M. Schmitt, L. Lu, Q. P. Dou Ubiquitin-proteasome pathway The ubiquitin-proteasome pathway (UPP) is critical to normal cellular function and, in , the Nobel Prize in Chemistry was awarded to its discoverers [1,2]. The major responsibility of . In Proteasome Inhibitors in Cancer Therapy, Julian Adams, the leader in developing the field, brings together a panel of highly experienced academic and pharmaceutical investigators to take stock of the remarkable work that has been accomplished to date, and examine emerging therapeutic possibilities for proteasome inhibitors in cturer: Humana.
Targeting proteasome in cancer cells increases the efficiency of cancer therapy. • Bortezomib is a first-in-class proteasome inhibitor with FDA approval. • Peripheral neuropathy is a dose-limiting toxic side effect of bortezomib. • The second-generation proteasome inhibitor carfilzomib is less by: Basic Proteasome Inhibitors In Cancer Therapy: Author: Oliver Sharp: Publisher: Tritech Digital Media: Publish Year: Language: English: Book ISBN: Book Price: $ Contact administrator to read this book. Sign in to read. In Proteasome Inhibitors in Cancer Therapy, Julian Adams, the leader in developing the field, brings together a panel of highly experienced academic and pharmaceutical investigators to take stock. These studies have lead to a new generation of proteasome inhibitors, some of them exhibiting the property of selective proteasome inhibition and efficacy in cancer therapy without inducing the Author: Ugo Testa.